Other News To Note

October 2011
BioWorld Today;10/6/2011, Vol. 22 Issue 194, p2
This section offers news briefs on the biotechnology industry. A 20 million dollar payment will be received by Agios Pharmaceuticals Inc. from Celgene Corp. A new drug application for ridaforolimus in metastatic soft-tissue or bone sarcomas from Ariad Pharmaceuticals Inc. and Merck & Co. Inc. has been accepted by the U.S. Food and Drug Administration (FDA). A drug discovery collaboration was made between Evotec AG and UCB SA to focus on the field of immunology.


Related Articles

  • Ariad Boosts Cash by $69M in Merck Revised Deal.  // Bioworld Week;5/10/2010, Vol. 18 Issue 19, p5 

    The article reports on the 50 million dollars worth of cash infusion to be given to Ariad Pharmaceuticals Inc. in Cambridge, Massachusetts following a revised deal with partner Merck & Co. Inc., wherein Merck will shoulder all of the development costs of Ariad's pipeline cancer drug...

  • Stock Movers.  // BioWorld Today;9/9/2013, Vol. 24 Issue 172, p2 

    A list of the stock market performance of biotechnology companies is presented including NASDAQ Biotechnology, Ariad Pharmaceuticals Inc. and Catalyst Pharmaceutical.

  • Biotechnology News Round-up.  // PharmaWatch: Biotechnology;Jun2010, Vol. 9 Issue 6, p2 

    The article offers world news briefs related to the biotechnology industry. Merck & Co. Inc. restructures its co-development and co-commercialization agreement with Ariad Pharmaceuticals Inc. for ridaforolimus inhibitor. Galapagos NV expands its global strategic alliance with Roche AB to develop...

  • Biotechnology Company Deals With Other Biotechnology Companies: June 1 - July 15, 2011.  // BioWorld Insight;7/18/2011, Vol. 19 Issue 29, p7 

    The article offers information on several deals among biotechnology companies from June 1 to July 15, 2011. It includes the collaboration between Advanced Cell Technology Inc. and Roslin Cells Ltd. to establish a human embryonic stem cell line bank in June. Deals in July include the agreement...

  • Ariad Exercises Option to co-promote Ridaforolimus.  // Bioworld Week;3/21/2011, Vol. 19 Issue 12, p5 

    The article focuses on the decision of Cambridge, Massachusetts-based Ariad Pharmaceuticals Inc. to exercise an option in a contract with its partner Merck and Co. Inc. to co-promote ridaforolimus, a drug for the treatment of sarcoma.

  • ASCO 2011 Roundup.  // BioWorld Today;6/7/2011, Vol. 22 Issue 109, p11 

    The article deals with the results reported by Merck & Co. Inc. and Ariad Pharmaceuticals Inc. from a Phase III trial of oral ridaforolimus in metastatic soft-tissue or bone sarcomas, during the 2011 annual meeting of the American Society of Clinical Oncology (ASCO).

  • Alliances News Headlines May 15, 2004 - June 14, 2004.  // PharmaWatch: Biotechnology;July 2004, Vol. 3 Issue 7, p14 

    Reports on developments related to pharmaceutical biotechnology industry in the U.S. from May 15, 2004 to June 14, 2004. Partnership between Evotec and Nuvios for the development of new drugs targeting osteoporosis; Collaboration between Teva Pharmaceutical Industries Ltd. and Active biotech AB...

  • Evotec enters into integrated drug discovery collaboration with UCB.  // PharmaWatch: CNS;Aug2011, Vol. 10 Issue 8, p19 

    The article announces that Evotec AG has entered into a three year integrated discovery collaboration with UCB SA to identify molecule moderators of priority biological targets involved in central nervous system (CNS) disorders.

  • Other News To Note.  // BioWorld International;7/13/2011, Vol. 16 Issue 28, p2 

    This section offers news briefs on the biotechnology industry. BioLineRx Ltd. is planning to list its shares through American Depositary Receipts to be traded on Nasdaq under the ticker BLRX. A collaboration has been signed by Evotec AG with UCB SA to discover small-molecule modulators of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics